Opioids Need Post-Marketing Data To Inform Abuse-Deterrent Claims, FDA Panel Says

Pfizer’s extended-release opioid Troxyca ER receives advisory committee recommendation for approval and two of three abuse-deterrent labeling claims, but members also want post-marketing data to help make future decisions.